ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings

Video

Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content